Business
Press Release Oct 26 2021
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 26, 2021, titled "Glenmark becomes the first company to launch Remogliflozin + Vildagliptin +Metformin fixed dose combination, at an affordable price for adults with Type 2 Diabetesin India".
About this update from Glenmark Pharmaceuticals Limited
[{"type":"text","content":" Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 26, 2021, titled \"Glenmark becomes the first company to launch Remogliflozin + Vildagliptin +Metformin fixed dose combination, at an affordable price for adults with Type 2 Diabetesin India\". View Attachment","length":442,"tagName":"div"}]